edoc

The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA ("Ecstasy") in Humans

Hysek, C. M. and Simmler, L. D. and Ineichen, M. and Grouzmann, E. and Hoener, M. C. and Brenneisen, R. and Huwyler, J. and Liechti, M. E.. (2011) The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA ("Ecstasy") in Humans. Clinical pharmacology and therapeutics, 90 (2). pp. 246-255.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A5849089

Downloads: Statistics Overview

Abstract

This study assessed the pharmacodynamic and pharmacokinetic effects of the interaction between the selective norepinephrine (NE) transporter inhibitor reboxetine and 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") in 16 healthy subjects. The study used a double-blind, placebo-controlled crossover design. Reboxetine reduced the effects of MDMA including elevations in plasma levels of NE, increases in blood pressure and heart rate, subjective drug high, stimulation, and emotional excitation. These effects were evident despite an increase in the concentrations of MDMA and its active metabolite 3,4-methylenedioxyamphetamine (MDA) in plasma. The results demonstrate that transporter-mediated NE release has a critical role in the cardiovascular and stimulant-like effects of MDMA in humans.
Faculties and Departments:05 Faculty of Science > Departement Pharmazeutische Wissenschaften > Pharmazie > Pharmazeutische Technologie (Huwyler)
03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Psychopharmacology Research (Liechti)
UniBasel Contributors:Huwyler, Jörg and Simmler, Linda and Liechti, Matthias Emanuel
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Mosby
ISSN:0009-9236
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:18 Aug 2020 08:48
Deposited On:14 Sep 2012 06:40

Repository Staff Only: item control page